Jason Harris

Senior Editor, OncLive®
Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for OncologyLive® and managing editor for Oncology Fellows and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: jharris@onclive.com

Articles

NK Cells Plus Bispecific Antibody Delivers Strong Results in Advanced Lymphoma

April 10th 2022

The innate cell engager AMF13 combined with preactivated and expanded natural killer (NK) cells induced “very encouraging activity” in patients with heavily pretreated lymphoma.

Temferon Displays Activity in Glioblastoma

April 8th 2022

Temferon, genetically modified Tie2-expressing monocytes targeting interferona2, showed the potential to activate the immune system and reprogram the tumor microenvironment in patients with glioblastoma.

NICE Makes Avelumab Available for Maintenance Treatment of Urothelial Cancer

April 8th 2022

Avelumab is now a treatment option for patients with urothelial cancer in the United Kingdom following a recommendation from the National Institute for Health and Care Excellence issued Thursday, April 7, 2022.1

Smile, Be Happy, and Work Hard

April 1st 2022

Evan B. Shereck, MD, MEd, talks about working with families experiencing incredible stress, the importance of wellness for both physicians and their partners, and making medical learning fun.

CAR T-Cell Therapy May Represent a New Option in Medullary Thyroid Cancer

April 1st 2022

Investigators at the Perelman School of Medicine at the University of Pennsylvania have recently initiated a clinical trial evaluating a novel CAR T-cell therapy in an effort to fill an unmet need for systemic treatment for patients with advanced incurable medullary thyroid cancer.

James Allison, PhD, to Lead New Immunotherapy Unit at MD Anderson

March 24th 2022

James P. Allison, PhD, a Nobel Laureate and Giants of Cancer Care® award winner, will head up the new James P. Allison Institute at The University of Texas MD Anderson Cancer Center.

Neoadjuvant Niraparib Shows Early Promise in BRCA-Mutated, HRD+ Ovarian Cancer

March 19th 2022

Neoadjuvant niraparib induced strong results for patients with BRCA-mutant, homologous repair deficient–positive advanced resectable ovarian cancer.

Antolitinic/Sintilimab Combination Under Investigation for OCCC in China

March 18th 2022

Chinese investigators have launched CC-ANNIE, a phase 2 trial exploring anlotinib plus sintilimab for women with recurrent platinum-resistant ovarian clear cell carcinoma.

Radiotherapy Treatments Are Getting Shorter and Faster in Prostate Cancer

March 17th 2022

The history of radiation therapy for men with prostate cancer extends back more than a century. From those early crude methods, the field has advanced to delivery potentially curative therapies that can be administered in as little as 2 weeks.

NICE Rejects Pembrolizumab Plus Chemotherapy for Select Metastatic TNBC

March 9th 2022

The United Kingdom’s National Institute for Health and Clinical Excellence has issued draft guidance recommending against pembrolizumab plus chemotherapy as a treatment for patients with metastatic triple-negative breast cancer whose tumors express PD-L1 with a combined positive score of 10 or more and who have not received chemotherapy for metastatic disease.

Neoadjuvant Immunotherapy/Chemotherapy Combos Gain in Prominence for Early-Stage TNBC

March 4th 2022

Immunotherapy treatment for early-stage triple-negative breast cancer is enjoying a boom period, though there are still unanswered questions, particularly around the optimal chemotherapy backbone and patient selection.

Breast Cancer Research Begins With Curiosity

March 4th 2022

Getting a start in clinical research can appear daunting, said Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C). Fortunately, all it really takes is a question and a bit of drive.

FDA Issues New Clinical Trial Guidelines to Further Cancer Therapy Development

March 1st 2022

New FDA guidelines reflect improvements in medical science over the past 6 years and are designed to facilitate continued advancement in cancer prevention, detection, research, and patient care.

Nearly 300 Novel Agents Currently in Development for Rare Cancers

February 24th 2022

New agents for rare cancers make up approximately 35% of drugs in the pipeline for all rare diseases, according to a report from the Pharmaceutical Research and Manufacturers of America.

Investigators Explore Metformin to Prevent Cancers in Li-Fraumeni Syndrome Carriers

February 22nd 2022

Individuals with Li-Fraumeni Syndrome, a rare hereditary condition, are at increased risk for a wide spectrum of malignancies, including breast cancer and sarcomas. Investigators are working to determine whether metformin, a drug indicated for diabetes and infertility caused by polycystic ovarian syndrome, can prevent cancers in LFS carriers.

Deep PSA Response Is Associated with Positive Wellbeing Scores in Advanced Prostate Cancer

February 17th 2022

Treatment with apalutamide, an androgen receptor inhibitor, was associated with a deep PSA response leading to beneficial outcomes in patient-related end points.

Apalutamide Outperforms Enzalutamide in mCSPC in Real-World Analysis

February 17th 2022

A greater portion of patients with metastatic castration-sensitive prostate cancer achieved an early and deep prostate-specific antigen reduction from baseline of 90% or more when treated with apalutamide compared with enzalutamide.

Senate Confirms Robert M. Califf as FDA Commissioner

February 17th 2022

The US Senate has confirmed Robert M. Califf, MD, a prominent cardiologist and expert in clinical trials, as the latest FDA commissioner today in a 50-46 vote.

ODAC Recommends New Trial Data of Sintilimab in US Population of Frontline NSCLC

February 10th 2022

The FDA’s Oncologic Drugs Advisory Committee voted against using single-country foreign data to support a biologics license application for sintilimab injection plus pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous non–small cell lung cancer.

Neoadjuvant Immunotherapy Proving to Be Effective, Safe Option in Lung Cancer

February 8th 2022

Checkpoint inhibitors are often used in the advanced stage, but Erin A. Gillaspie, MD, MPH, argues that the data show physicians should consider utilizing this class of agents earlier in treatment.